Tags

Type your tag names separated by a space and hit enter

Serum FGF21 in girls with anorexia nervosa - comparison to normal weight and obese female adolescents.
Neuro Endocrinol Lett 2017; 38(3):173-181NE

Abstract

BACKGROUND

Fibroblast growth factor 21 (FGF21) is a hepatokine, myokine and adipokine of a potent influence to energy homeostasis. Data according its serum concentrations in AN are contradictory.

OBJECTIVES

Analysis of serum FGF21 in girls with acute anorexia nervosa and comparison the results with normal weight and obese female adolescents considering their nutritional status, carbohydrate and lipid metabolism.

METHODS

Serum FGF21 concentrations were evaluated using commercially available ELISA kit in 32 Polish girls with restrictive AN (AN), 29 girls with obesity (O) and 21 healthy controls (C). Anthropometric measurements (weight, height, BMI) and laboratory assays (serum fasting glucose, insulin, HOMA-IR, total cholesterol, HDL, LDL, triglycerides, C-reactive protein) were performed.

RESULTS

Mean serum FGF-21 in the AN group was significantly lower, whereas in the O group it was significantly higher than in healthy controls. In all examined girls significant positive correlations between FGF21 and BMI were noted. We also observed significant positive relationships between serum FGF21 levels and fasting glucose, triglycerides, CRP, insulin and HOMA-IR. In all examined girls serum concentrations of this hormone correlated negatively with age and HDL-cholesterol levels.

CONCLUSIONS

1) Serum FGF21 concentrations are decreased in AN and elevated in obesity. They are independently and positively related to BMI and insulin resistance; 2) Decreased serum FGF21 in AN may support the maintenance of normal blood glucose through adjustment the insulin levels and insulin sensitivity; 3) Elevated FGF21 levels in obesity may be considered adaptive mechanism preventing insulin resistance and its metabolic consequences.

Authors+Show Affiliations

Department of Physiology, Pathology and Neonatal Intensive Care, Multidisciplinary Hospital in Gliwice, ul. Kościuszki 1, 44-100 Gliwice, Poland.Chair and Department of Pediatrics, School of Medicine with Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, ul. 3 Maja 13/15, 41-800 Zabrze, Poland.Chair and Department of Medical and Molecular Biology, School of Medicine with Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, ul. Jordana 19, 41-808 Zabrze, Poland.Institute of Medicine, Jan Grodek State Vocational School in Sanok, ul. Mickiewicza 21, 38-500 Sanok, Poland.Chair and Department of Pediatrics, School of Medicine with Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, ul. 3 Maja 13/15, 41-800 Zabrze, Poland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28759185

Citation

Mikolajczak, Agata, et al. "Serum FGF21 in Girls With Anorexia Nervosa - Comparison to Normal Weight and Obese Female Adolescents." Neuro Endocrinology Letters, vol. 38, no. 3, 2017, pp. 173-181.
Mikolajczak A, Oswiecimska JM, Swietochowska E, et al. Serum FGF21 in girls with anorexia nervosa - comparison to normal weight and obese female adolescents. Neuro Endocrinol Lett. 2017;38(3):173-181.
Mikolajczak, A., Oswiecimska, J. M., Swietochowska, E., Roczniak, W., & Ziora, K. T. (2017). Serum FGF21 in girls with anorexia nervosa - comparison to normal weight and obese female adolescents. Neuro Endocrinology Letters, 38(3), pp. 173-181.
Mikolajczak A, et al. Serum FGF21 in Girls With Anorexia Nervosa - Comparison to Normal Weight and Obese Female Adolescents. Neuro Endocrinol Lett. 2017;38(3):173-181. PubMed PMID: 28759185.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum FGF21 in girls with anorexia nervosa - comparison to normal weight and obese female adolescents. AU - Mikolajczak,Agata, AU - Oswiecimska,Joanna M, AU - Swietochowska,Elzbieta, AU - Roczniak,Wojciech, AU - Ziora,Katarzyna T, PY - 2017/03/21/received PY - 2017/04/02/accepted PY - 2017/8/2/pubmed PY - 2018/5/4/medline PY - 2017/8/1/entrez SP - 173 EP - 181 JF - Neuro endocrinology letters JO - Neuro Endocrinol. Lett. VL - 38 IS - 3 N2 - BACKGROUND: Fibroblast growth factor 21 (FGF21) is a hepatokine, myokine and adipokine of a potent influence to energy homeostasis. Data according its serum concentrations in AN are contradictory. OBJECTIVES: Analysis of serum FGF21 in girls with acute anorexia nervosa and comparison the results with normal weight and obese female adolescents considering their nutritional status, carbohydrate and lipid metabolism. METHODS: Serum FGF21 concentrations were evaluated using commercially available ELISA kit in 32 Polish girls with restrictive AN (AN), 29 girls with obesity (O) and 21 healthy controls (C). Anthropometric measurements (weight, height, BMI) and laboratory assays (serum fasting glucose, insulin, HOMA-IR, total cholesterol, HDL, LDL, triglycerides, C-reactive protein) were performed. RESULTS: Mean serum FGF-21 in the AN group was significantly lower, whereas in the O group it was significantly higher than in healthy controls. In all examined girls significant positive correlations between FGF21 and BMI were noted. We also observed significant positive relationships between serum FGF21 levels and fasting glucose, triglycerides, CRP, insulin and HOMA-IR. In all examined girls serum concentrations of this hormone correlated negatively with age and HDL-cholesterol levels. CONCLUSIONS: 1) Serum FGF21 concentrations are decreased in AN and elevated in obesity. They are independently and positively related to BMI and insulin resistance; 2) Decreased serum FGF21 in AN may support the maintenance of normal blood glucose through adjustment the insulin levels and insulin sensitivity; 3) Elevated FGF21 levels in obesity may be considered adaptive mechanism preventing insulin resistance and its metabolic consequences. SN - 0172-780X UR - https://www.unboundmedicine.com/medline/citation/28759185/Serum_FGF21_in_girls_with_anorexia_nervosa___comparison_to_normal_weight_and_obese_female_adolescents_ L2 - https://medlineplus.gov/obesity.html DB - PRIME DP - Unbound Medicine ER -